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Introduction
 Head and neck squamous cell carcinoma 
(HNSCC) is the sixth most common malignant 
tumor worldwide, with an estimated incidence of 
500,000 annually1,2.  Over 50％ of HNSCCs arise 
in the oral cavity.  Despite aggressive and often 
mutilating therapeutic regimens, overall survival 
in HNSCCs, including oral cancers, has remained 
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Abstract : Cyclin D1 gene (CCND1) numerical aberrations are independent prognostic indicators 
of head and neck squamous cell carcinomas (HNSCCs).  High epidermal growth factor receptor 
gene (EGFR) copy number is associated with poor prognosis in lung cancer, but such ﬁndings are 
controversial in oral SCCs (OSCCs).  We analyzed copy number status in CCND1 and EGFR in 
OSCC patients and its association with clinical outcome.
　EGFR and CCND1 statuses were analyzed in 85 OSCC patients by ﬂuorescence in situ hybrid-
ization (FISH) of specimens obtained by ﬁne-needle aspiration biopsy.
　CCND1 numerical aberration was found in 35 of 85 tumors (41％), and aberrant EGFR copy 
number was observed in 36 (42％).  Gene ampliﬁcation (GA) was dominant among CCND1 copy 
number changes (14/35 :40％).  Balanced trisomy (BT) was the most frequently observed EGFR ab-
erration (17/36 :47％).  In a multivariate Cox's proportional hazards analysis, CCND1 GA was cor-
related with disease-free survival (P＜ 0.001), whereas EGFR BT was signiﬁcantly correlated with 
overall survival (P＝ 0.001).  Patients with a combination of CCND1 GA and/or EGFR BT had sig-
niﬁcantly poorer clinical outcome.
　CCND1 and EGFR copy number changes were frequent in OSCC and had differing aberration 
patterns.  CCND1 GA and EGFR BT statuses by dual-color FISH were the predominant predictors 
of clinical outcome.  Further investigation is needed to determine the implications for EGFR inhibi-
tor therapy in OSCC.
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largely unchanged over the past 20 years3,4.  To 
improve the long-term survival rate of patients 
with this malignant tumor, it is important that we 
ﬁnd more accurate prognostic markers that can 
identify patients with a high risk of recurrence 
and thus enable us to give more effective treat-
ment.
 Chromosomal aberration of the 11q13 region 
has been detected in HNSCC5,6.  This region 
encompasses several putative oncogenes : CCND1 
(cyclin D1) is the major target for study because 
the amplicon of the 11q13 region always includes 
CCND1 and is consistently ampliﬁed and overex-
pressed in tumor cells7.  Several studies have 
reported that gene, chromosomal abnormalities 
and/or overexpression of CCND1 is signiﬁcantly 
correlated with aggressive tumor growth and poor 
outcome, thus this gene might be useful as a prog-
nostic indicator in HNSCC8‒16.  Since 1998, we 
have been investigating CCND1 deregulation by 
using dual-color ﬂuorescence in situ hybridization 
with ﬁne needle aspiration (FNA-FISH) of pri-
mary oral squamous cell carcinomas (OSCCs). 
We have revealed that: 1) CCND1 ampliﬁcation 
detected by FISH is a more reliable prognostic 
indicator than cyclin D1 protein overexpression ; 2) 
tumors with aberrant copy numbers of CCND1 
always overexpress cyclin D1 protein ; and 3) these 
CCND1 numerical aberrations are signiﬁcantly 
associated with invasive tumor phenotype and 
pathologically determined lymph node metasta-
sis12,13 and are valuable in identifying patients at 
high risk of late lymph node metastasis in stage I/
II OSCC14.
 Epidermal growth factor receptor (EGFR) is a 
member of the ErbB family of tyrosine kinase 
receptors, the ligands of which are epidermal 
growth factor (EGF) and transforming growth fac-
tor alpha (TGF-α).  EGFR is overexpressed in 
many kinds of solid tumors, including approxi-
mately 80％ of HNSCCs17.  Overexpression of this 
protein is associated with advanced-stage HNSCC 
and poor survival18.  Recently, several clinical tri-
als of EGFR inhibitors in treating patients with 
HNSCC have demonstrated a clear beneﬁt of 
these drugs in a small subset of patients.  In 
phase II studies of patients with recurrent or met-
astatic HNSCC, several EGFR inhibitors have 
shown encouraging clinical activity19,20.  Moreover, 
a large, randomized, phase III trial has shown 
that a combination of EGFR inhibitors and radia-
tion therapy in locally advanced HNSCC signiﬁ-
cantly prolongs overall survival21.  Therefore, a 
subset of HNSCC tumors respond to EGFR inhibi-
tors, and it is critical that we are able to select 
those patients who will respond.  The identiﬁca-
tion of predictive markers for treatment response 
to these drugs is also a task of high priority.  In 
non-small-cell lung cancer (NSCLC), increased 
EGFR copy number, as assessed by FISH, is asso-
ciated with poor prognosis22 and is signiﬁcantly 
correlated with better clinical outcome in EGFR 
inhibitor-treated patients23,24, suggesting that the 
copy number of this gene may be a useful predic-
tor in patients treated with EGFR inhibitors. 
However, this association has not yet been clearly 
demonstrated in HNSCCs, including in oral can-
cer.  Furthermore, recently, Kalish et al. suggested 
that deregulated cyclin D1 overexpression may be 
associated with resistance of HNSCC to EGFR 
inhibitors25.  Thus, from not only a prognostic but 
also a therapeutic point of view, the simultaneous 
assessment of CCND1 and EGFR copy number in 
OSCC by dual-color FISH is essential.
 To elucidate the nature of CCND1 and EGFR 
alterations in OSCC, we used dual-color FISH of 
FNA biopsy samples to examine CCND1 and 
EGFR copy numbers and alteration patterns in 85 
OSCCs, and we correlated the results with clinical 
parameters and patient outcome.
Patients and Methods
1. Patients and Tissue Samples
 The samples were taken from OSCC specimens 
resected by primary surgical excision from 85 
patients between 1999 and 2005 at the Maxillofa-
cial Surgery, Graduate School, Tokyo Medical and 
Dental University (Tokyo, Japan) (Table 1).  None 
of the patients had received pre- or postoperative 
treatment.  The study was approved by the insti-
tution's review board, and informed consent was 
obtained from all patients.  Clinicopathologic stag-
ing and historical grading of tumors followed the 
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current International Union Against Cancer TNM 
classiﬁcation26 and the World Health Organization 
classiﬁcation27 respectively.
2. FNA Biopsy and FISH Analyses
 Tumor cell sampling and slide preparation for 
FISH assay were performed as described previ-
ously12.  A suspension of single cells was obtained 
by aspirating the tumor with a 21-gauge needle. 
The cells were soaked in 0.05 M KCl solution for 2 
min to disrupt the cell membranes and expose the 
naked nuclei, and then ﬁxed by addition of an 
equal volume of methanol/acetic acid (3 :1) solu-
tion (Carnoy).  After centrifugation at 3000 revolu-
tions per minute (rpm) for 10 minutes, the upper 
layer was exchanged for Carnoy solution.  Centrif-
ugation and solution exchange were repeated 
twice and the resulting upper layer was trans-
ferred dropwise to glass slides under steam.
 To detect changes in CCND1 and EGFR copy 
number in the oral SCC cells, we used two types of 
dual color bacterial artiﬁcial chromosome clone 
probes that were speciﬁc for those two genes.
 FISH assays were performed with the LSI 
CCND1 SpectrumOrange/CEP 11 SpectrumGreen 
and EGFR SpectrumOrange/CEP 7 SpectrumGreen 
Table 1　Correlation between CCND1, EGFR positive and clinicopathologic parameters
P＊
Clinicopathologic
parameters
No. of patients
CCND1 polysomy or 
gene ampliﬁcation
EGFR trisomy
Age, y
　＞ 60 38
　＜ 60 47 NS 0.05
Gender
　Male 53
　Female 32 NS NS
Tumor site
　Tongue 48
　Upper gingiva  4
　Lower gingiva 22
　Floor of mouth  6
　Buccal mucosa  5 NS NS
Clinical Stage
　I 24
　II 38
　III  7
　IV 16 NS NS
Cellular differentiation
　Well to Moderate 70
　Poor 15 NS NS
Mode of Invasion
　1–3 51
　4C to 4D 34 0.027 NS
LN metastasis＊＊ 38 0.003 NS
Distant metastasis 12 0.003 NS
Recurrence 37 ＜ 0.001 0.012
Cancer death 20 0.001 0.001
NS indicates not signiﬁcant.
＊P values were determined by the chi-squared test and two-tailed Fisher exact test.
＊＊Histopathologic diagnosis.
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probe (Vysis/Abbott Molecular, Des Plaines, IL). 
Dual-color FISH was carried out as follows. 
Brieﬂy, the materials on the slides were aged in 
2× saline-sodium citrate (SSC)/0.1％ (v/v) NP-40 
at 37℃ for 30 minutes and dehydrated through an 
ethanol series.  The slides were denatured in 70％ 
(v/v) formamide/2× SSC at 75℃ for 5 minutes 
and dehydrated through an ethanol series.  The 
probe, denatured at 75℃ for 5 minutes, was 
placed on denatured slides, covered with Paraﬁlm 
(American National Can, Greenwich, CT), and 
incubated in a humid box at 37℃ overnight.  After 
being washed at 45℃ three times in freshly pre-
pared 50％ (v/v) formamide/2× SSC for 10 min-
utes, SSC for 10 minutes, and 2× SSC/0.1％ (v/v) 
NP-40 for 5 minutes, the slides were counter-
stained with 4,6-diamidino-2-phenylindole, dihy-
drochloride (DAPI : 1 μg/ml).
3. Fluorescence Microscopy
 An Olympus BX50 epiﬂuoresence microscope 
equipped with ×60 and ×100 oil-immersion 
objectives and a triple-pass ﬁlter for Spectrum 
Green/Spectrum Orange and DAPI (Vysis Inc, 
Downers Grove, IL) was used to count the ﬂuores-
cent signals.  Overlapping and damaged nuclei 
were ignored and only intact nuclei were evalu-
ated. Hybridization signals were counted in 100 
interphase nuclei.  The copy numbers of EGFR 
and chromosome 7 centromere signals or CCND1 
and chromosome 11 centromere signals were 
counted for each nucleus.
4. Evaluation of FISH Analysis
 The following criteria were deﬁned for analysis : 
for each FISH probe tested, the status of the chro-
mosome used as control was classiﬁed as disomy, 
trisomy, or polysomy when, respectively, on aver-
age 2.5, 2.6–3.0 and more copies were scored per 
nucleus.  FISH patterns were considered balanced 
when the ratio gene/chromosome copy number per 
cell was 0.9–1.2.  When average ratio gene/chro-
mosome copy number was ＞ 1.2 and the gene/cell 
ratio ＞ 3.0, it was classiﬁed as gene ampliﬁcation 
(GA)12‒14,28,29.  According to the criteria shown in 
Table 2, tumors were classiﬁed as showing bal-
anced disomy (BD), balanced trisomy (BT), bal-
anced polysomy (BP), or gene ampliﬁcation (GA).
5. Statistical Analysis
 The dual-color FISH results were compared 
with the clinicopathologic information.  Statistical 
analyses were carried out with SPSS11.0J soft-
ware (SPSS Japan Inc.).  The results of dual-color 
FISH were compared with clinicopathologic infor-
mation using the chi-squared test and two-tailed 
Fisher exact test.  The clinicopathologic informa-
tion included patient age, gender, tumor site, dis-
ease stage, histopathologic grading, presence of 
lymph node metastasis, and the mode of invasion 
according to the modiﬁed Jacobsson criteria.
 Multivariate Cox's proportional hazards analy-
sis were used to compare the FISH results across 
levels of clinicopathologic parameters.  Disease-
free survival (DFS) and overall survival (OS) rates 
were also calculated by the Kaplan-Meier method, 
and statistical signiﬁcance was determined by the 
log rank test.
Results
1. Patient Characteristics
Table 2　 Gene and chromosome FISH status
CCND1 EGFR Criteria
Patients Patients Average Average Average
FISH status No. ％ No. ％ chromosome/cell gene/chromosome gene/cell
Balanced disomy (BD) 50 58.8 49 57.6 ＜ 2.5 0.9–1.2 －
Balanced trisomy (BT)  8  9.4 17 20.0 2.6–3.0 0.9–1.2 －
Balanced polysomy (BP) 13 15.3 13 15.3 3.0＜ 0.9–1.2 －
Gene ampliﬁcation (GA) 14 16.5  6  7.1 － 1.2＜ 3.0＜
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 Tumor cells were collected from the surgical 
specimens of 85 patients with OSCC.  Patient 
characteristics are summarized in Table 1.  The 
median follow-up time after surgery was 1383 
days (range 674–2912 days).  Postoperative recur-
rence, including late cervical lymph node metasta-
sis, distant metastasis, and locoregional recur-
rence, occurred in 37 patients.
2. CCND1 and EGFR Copy Numbers
 All 85 OSCC samples were successfully scored 
for CCND1 and EGFR FISH status.  For CCND1, 
there were 50 tumors with BD FISH status (59％), 
8 with BT (9％), 13 with BP (15％), and 14 with 
GA (17％, Fig. 1 and Table 2).  Thus, CCND1 
numerical aberration was found in 35 tumors 
(41％), and GA and BP were the dominant abnor-
mities of this gene.  Thirty-six (42％) of the 85 
tumors exhibited abnormal EGFR copy numbers : 
17 with BT (20％), 13 with BP (15％), and 6 with 
GA (7％, Fig. 1 and Table 2).  Therefore, BT was 
the most frequently observed EGFR copy number 
aberration.  Unbalanced gene loss was not observed 
in the 85 tumors.
3.  Association between CCND1 and EGFR 
Statuses and Survival
 The Kaplan-Meier survival curves for DFS and 
OS (Fig. 2A, 2B) clearly demonstrated the adverse 
impact of positive CCND1 BP or GA status on 
both disease recurrence (BP: log rank P＝ 0.0016 ; 
GA: log rank P＜ 0.0001) and OS (BP : log rank 
P＝ 0.0248; GA: log rank P＝ 0.0014).  For EGFR, 
the DFS and OS curves of patients with abnormal 
copy numbers (BP, BT, or GA) were shorter than 
those of patients with normal copy number (BD). 
However, positive EGFR BT status was the only 
abnormality signiﬁcantly associated with worse 
DFS (log rank P＝ 0.0068) and OS (log rank P＝
0.002) (Fig. 2C, 2D).  The correlation between 
CCND1 polysomy or gene ampliﬁcation and/or 
EGFR trisomy and clinicopathologic parameters 
Fig. 1　Evaluation of gene copy number by ﬂuorescent in situ hybridization (FISH). 
Cells are hybridized with probes for the chromosome 11 centromere (green) 
and CCND1 (orange). CCND1 balanced disomy (BD) is normal gene copy 
number (A), balanced trisomy (BT) of CCND1 (B）, balanced  polysomy (BP) 
of CCND1 (C), and gene ampliﬁcation (GA) of CCND1 (D).
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in patients with oral SCCs is also summarized in 
Table 1.  The presence of CCND1 polysomy or 
gene ampliﬁcation was not correlated signiﬁcantly 
with age, gender, tumor site or tumor clinical 
stage.  Although CCND1 polysomy or gene ampli-
ﬁcation occurred more frequently in advanced-
stage or poorly differentiated tumors, these differ-
ences were not statistically signiﬁcant.  However, 
a more diffuse invasive pattern (mode of invasion : 
Grade 4C, 4D) was signiﬁcantly associated with 
this genetic abnormality (chi-squared and two-
tailed Fisher exact for trend, P＝ 0.027).  More-
over, these FISH statuses of CCND1 were signiﬁ-
cantly correlated with pathologic lymph node 
status (P＝ 0.003), distant metastasis (P＝ 0.003) 
disease recurrence (P＜ 0.001), and survival (P＝
Fig. 2　Kaplan-Meier plots for CCND1 (A) disease-free survival, (B) overall survival, for EGFR (C) 
disease-free survival, (D) overall survival, and for combined CCND1 gene ampliﬁcation and 
EGFR trisomy (E) disease-free survival, (F) overall survival. CCND1－; CCND1 BD, BT or BP, 
EGFR－; EGFR not BT, CCND1＋; CCND1 GA and EGFR＋; EGFR BT.
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0.001).
 On the other hand, EGFR trisomy was signiﬁ-
cantly correlated with patient age (P＝ 0.05), and 
this genetic aberration was signiﬁcantly associ-
ated with disease recurrence and survival (P＝
0.012 and P＝ 0.001, respectively).  However, this 
abnormality was not signiﬁcantly correlated with 
other clinicopathologic factors, and the correlation 
with pathologic lymph node status and distant 
metastasis just failed to reach statistical signiﬁ-
cance.  Table 3 shows the correlation between 
CCND1 and EGFR FISH status.  Nine (35％) of 
the 26 patients with tumors demonstrating 
CCND1 polysomy or gene ampliﬁcation concomi-
tantly exhibited EGFR trisomy.  Thus, there was 
signiﬁcant association between CCND1 and EGFR 
by FISH analysis (P＝ 0.025).
 Multivariate Cox's proportional hazards analy-
sis including clinicopathologic factors and FISH 
status revealed that male (hazard ratio 2.2, P＝
0.045), poor cellular differentiation (hazard ratio 
2.2, P＝ 0.029), and positive CCND1 GA status 
(hazard ratio 4.6, P＜ 0.001) were independent 
prognostic indicators of poorer DFS.  Male (hazard 
ratio 4.0, P＜ 0.032), clinical stage III/IV (hazard 
ratio 4.2, P＝ 0.005), and positive EGFR BT sta-
tus (hazard ratio 6.6, P＝ 0.001) were indepen-
dent prognostic indicators of poorer OS (Table 4).
4.  Association of Combined CCND1 and EGFR 
Status with Disease Outcome in Oral SCC
 Given that positive CCND1 GA status was an 
independent predictor of DFS and positive EGFR 
BT status was an independent predictor of OS, we 
attempted to obtain further information by ana-
lyzing subgroups on the basis of combined CCND1 
Table 3　Association between CCND1 and EGFR FISH status
CCND1 polysomy or gene ampliﬁcation
EGFR trisomy Positive Negative Total
Positive  9  8 17
Negative 17 51 68
　　　　　Total 26 59 85
P＝ 0.025
Table 4　Multivariate Cox proportional hazard analysis
Disease-free survival Overall survival
　 Risk ratio 95％ Cl Risk ratio 95％ Cl
Age － － － －
Gender (male) 2.202 1.016–4.770 4.000 1.129–14.169
Tumor site － － － －
Tumor size － － － －
Clinical stage I-II vs. III-IV － － 4.224 1.672–10.675
Cellular differentiation 2.211 1.085–4.508 － －
/CCND1/
Balanced disomy － － － －
Balanced trisomy － － － －
Balanced polysomy － － － －
Gene ampliﬁcation 4.637 2.086–10.309 － －
/EGFR/
Balanced disomy － － － －
Balanced trisomy － － 6.589 2.260–19.211
Balanced polysomy － － － －
Gene ampliﬁcation － － － －
15May, 2009 Genetic Alterations of Cyclin D1 and EGFR in OSCCs
and EGFR FISH statuses.  Four subgroups (posi-
tive or negative status for CCND1 GA and EGFR 
BT) were assigned to DFS and OS curves.  DFS 
and OS in patients whose tumors exhibited at 
least positive CCND1 GA or EGFR BT status 
(Groups ＋/＋, ＋/–, and – /＋) were signiﬁcantly 
lower than in Group – /–.  There were no signiﬁ-
cant differences in DFS and OS rates among these 
three groups (＋/＋, ＋/–, and – /＋) (Fig. 2D, 2E).
Discussion
 We explored the relationship between CCND1 
and EGFR genetic statuses in 85 untreated 
OSCCs assessed by FISH of FNA biopsies, as well 
as the association between FISH status and prog-
nosis.  We clearly demonstrated that the majority 
of OSCC tumors exhibited copy number changes 
in these two genes, and that these genetic aberra-
tions were signiﬁcantly correlated with aggressive 
tumor behavior and poorer prognosis.  Interest-
ingly, we revealed that the dominant genetic 
abnormality patterns vary between CCND1 and 
EGFR.
 To the best of our knowledge, this is the ﬁrst 
simultaneous dual-color FISH assessment of 
CCND1 and EGFR copy number in the same 
OSCC tumor specimens and the ﬁrst study to cat-
egorize FISH status into four subtypes (BD, BT, 
BP, and GA) and investigate each genetic abnor-
mality as a prognostic indicator for this cancer. 
CCND1 numerical aberrations were found in 35 
(41％) of all 85 primary OSCCs.  GA was seen in 
14 (40％) of these 35 patients and was the most 
frequently identiﬁed aberration.  In the Kaplan-
Meier estimate, the DFS and OS curves of 
patients with CCND1 GA or BP were signiﬁcantly 
shorter than the curves of patients without 
CCND1 numerical aberrations.  These ﬁndings 
are in keeping with the evidence that CCND1 
numerical aberrations, as detected by FISH of 
FNA biopsy samples of primary OSCCs, may be 
useful predictors of recurrence and survival in 
patients with these cancers12‒14,29.  Thirty-six (42％) 
of the patients had tumors with increased num-
bers of EGFR copies per cell, most of them with 
BT (17 cases : 47％) or BP (13 cases : 36％).  GA 
was found in only 17％ of patients whose tumors 
showed EGFR copy number aberrations ; it was 
therefore far less common than in the CCND1 
aberrations.  This ﬁnding is consistent with the 
results of previous reports22,30.  Kaplan-Meier sur-
vival curves for DFS and OS clearly demonstrated 
the adverse impact of EGFR BT on both disease 
recurrence and OS.  However, our multivariate 
Cox's proportional hazards analysis determined 
that EGFR BT was signiﬁcantly correlated with 
OS alone and was one of the dominant predictors 
of OS in OSCC patients.
 Many studies have investigated the role of 
CCND1 abnormalities in the tumorigenesis of 
HNSCCs including oral SCCs.  Those studies 
revealed that ampliﬁcation or overexpression of 
CCND1 might be a valuable biologic marker of 
poor prognosis, tumor aggressiveness, and local 
and regional recurrence of these malignan-
cies15,16,31.  Since 1998, we have been investigating 
CCND1 deregulation using FISH of FNA biopsies 
from primary oral SCCs, and have demonstrated 
clearly that it is possible to investigate chromo-
somal aberrations, such as ampliﬁcations, dele-
tions and chromosomal rearrangements, in these 
carcinomas using this technique.  We have demon-
strated that CCND1 numerical aberration is sig-
niﬁcantly associated with an invasive phenotype 
and cervical lymph node metastasis, and that this 
genetic alteration is a reliable predictor of out-
come in oral SCCs12‒14.  In the current study, we 
observed CCND1 polysomy or ampliﬁcation in 27 
of 85 primary oral SCCs (31.8％), and these were 
signiﬁcantly associated with aggressive tumor 
behavior and poorer survival (Table 1).
 On the other hand, gene ampliﬁcation and over-
expression of EGFR have been reported in various 
human cancers including oral SCCs.  Yamamoto et 
al. has demonstrated that EGFR gene ampliﬁca-
tion and overexpression is found in many human 
squamous cell carcinoma cell lines32.  Kamata et 
al. has also reported the growth inhibitory effect 
of EGF and the sensitivity to the inhibitory effect 
of EGF correlated with the level of EGFR in 12 
SCC cell lines including oral cavity33, however the 
role of those aberrations in the tumorigenesis of 
human SCCs is unclear.  There have been several 
conﬂicting reports on the association between 
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EGFR protein expression level and gene copy 
number.  Many studies have indicated that EGFR 
copy number is signiﬁcantly correlated with pro-
tein expression in many human malignancies, 
including non-small-cell lung cancer and laryngeal 
and esophageal cancers22,28,34.  In contrast, several 
other studies have found no signiﬁcant association 
between EGFR protein expression level and EGFR 
FISH status in HNSCC35,36.  These discrepancies 
may result from differences in the site and histol-
ogy of the tumor, patient numbers, case heteroge-
neity, and the methods used to assess EGFR. 
Therefore, this issue remains a matter of contro-
versy, and further investigations will be required 
to clarify whether EGFR protein expression level 
is indeed correlated with gene gain of copy num-
ber.
 We also demonstrated that EGFR trisomy was 
signiﬁcantly correlated with age of patient in the 
current study, but none of the other histopatholog-
ical parameters was statistically signiﬁcant.  A 
negative correlation between EGFR genetic abnor-
malities or overexpression and clinical features, 
such as metastasis, or histopathological charac-
ters in the HNSCCs including oral SCCs has been 
reported36,37.  The question arises as to why EGFR 
trisomy is the strongest predictor.  To address this 
question, we examined the correlation between 
EGFR and centromere of chromosome 7 FISH sta-
tus ; we found a signiﬁcant positive correlation 
between the two genetic factors (Spearman's rho＝
0.925, P＜ 0.001).  Moreover, we investigated the 
association between chromosome 7 copy number 
status and clinical outcome in OSCC, and found 
that tumors with chromosome 7 trisomy had the 
worst survival curves of the three chromosome 7 
FISH statuses of disomy, trisomy and polysomy 
(data not shown).  These associations are the 
likely reason why the EGFR BT aberration was 
the most signiﬁcant predictor of OS.  To our 
knowledge, the association between chromosome 7 
copy number and clinical outcome in OSCC has 
not been reported previously, although Gebhart et 
al. examined 35 OSCCs by comparative genomic 
hybridization, and those patients whose tumors 
showed a gain of chromosome 7p, including band 
p12, had higher rates of relapse and worse sur-
vival38.  Chromosome 7 aneusomy has been found 
in various carcinomas of the body, such as pros-
tate, lung, larynx, and head and neck22,30,34,39. 
Several groups have demonstrated that aneusomy 
of chromosome 7 is associated with higher pros-
tate cancer grade, advanced pathological stage, 
and shorter survival30,40.  In contrast, in HNSCC, 
Joris et al. used tissue in situ hybridization to 
investigate changes in chromosome constitution 
with carcinogenesis in laryngeal SCCs and found 
that 12 (75％) of 16 tumors showed chromosome 
copy number imbalances and/or polysomy of chro-
mosome 1 and 7 ; these changes were signiﬁcantly 
negatively correlated with cancer-free survival 
rates41.  However, they did not clearly demonstrate 
the association between chromosome 7 aneusomy 
and prognosis in laryngeal SCC.  Therefore, fur-
ther work is required to clarify whether chromo-
some 7 copy number changes are in fact correlated 
with prognosis in HNSCCs including oral cancer.
 Of particular interest was the ﬁnding that the 
dominant genetic abnormality patterns vary 
between CCND1 and EGFR.  Different mecha-
nisms may contribute to the development of this 
discrepancy in genetic status.  Recently, Reshmi 
and Gollin reviewed several sources of chromo-
somal instability that accounted for the mecha-
nisms by which aneuploidy and gene ampliﬁcation 
arise42.  Our results clearly demonstrated that GA 
was the most frequently detected aberration of 
CCND1.  The chromosomal location of CCND1 
may be intimately associated with this genetic 
abnormality.  CCND1 is located on 11q1342, and 
several fragile sites have been identiﬁed in and 
around this chromosomal locus.  These fragile 
sites are thought to be sites of chromosomal break-
age, and breakage-fusion-bridge (BFB) cycles may 
lead to gene ampliﬁcation at this site43,44.  There-
fore, it is possible that the ampliﬁcation of CCND1 
in band 11q13 may be due to its chromosomal 
location―i.e. in a hotspot for chromosomal break-
age.  For EGFR, BT and BP were the dominant 
genetic abnormalities, suggesting that copy num-
ber changes in this gene were signiﬁcantly associ-
ated with chromosome 7 copy number.  In general, 
chromosome aneusomy may be caused by DNA 
aneuploidy, which may in turn be due to genetic 
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instability resulting from aberrations in tumor 
suppressor genes or oncogenes.  This may be one 
of the mechanisms that affect EGFR FISH status.
 Over the last few years, a substantial amount of 
structural data has illuminated the role of EGFR 
in human cancers.  EGFR activates a variety of 
intracellular pathways and proteins that stimu-
late growth, proliferation, angiogenesis, metasta-
sis, and survival, including the Ras/Raf/MAPK 
(Mitogen-Activated Protein Kinese), PI3K (phos-
phatidylinositol-3 kinase)/Akt, phospholipase-Cγ, 
STATs (signal transducers and activators of tran-
scription), and Src kinase pathways45.  Signal 
transducers and activators of transcription 3 
(STAT3) represent a point of convergence for sev-
eral upstream signaling pathways, including 
EGFR, platelet-derived growth factor receptor, 
Src, Bcr-Abl, and gp130/IL-6R where activation of 
STAT3 elicits expression of a variety of target 
genes, including Bcl-XL, MMP-9, VEGF, MMP-2, 
and cyclin D146‒51.
 Recently, several in vitro studies have suggested 
that cyclin D1 plays a critical role in EGFR-driven 
tumorigenesis and that deregulated cyclin D1 
overexpression may be signiﬁcantly associated 
with resistance of HNSCC to EGFR inhibitors25. 
This suggested that CCND1 is a pivotal down-
stream target gene in the EGFR pathway, and 
that to predict the prognosis of patients with 
OSCCs and the therapeutic effectiveness of EGFR 
inhibitors we need to investigate the genetic sta-
tus of not only EGFR but also CCND1.  We there-
fore performed a simultaneous assessment of 
CCND1 and EGFR genetic status, using FISH of 
FNA biopsy samples to deﬁne subgroups of 
patients at increased risk of disease recurrence 
and poor prognosis.  We clearly demonstrated that 
DFS and OS of patients with CCND1 GA and/or 
EGFR BT (Groups ＋/＋, ＋/–, and – /＋) were sig-
niﬁcantly lower than in patients without these 
genetic abnormalities.  In addition, there were no 
signiﬁcant differences among these three groups 
in terms of DFS and OS, thus we did not deter-
mine the synergistic effect of these two genes on 
prognosis.  This ﬁnding suggests that CCND1 and 
EGFR genetic abnormalities equally contribute to 
clinical impact on prognosis in OSCC patients. 
However, the mechanism by which these mole-
cules contribute to the initiation and/or progres-
sion of this cancer is not clear. Additional studies 
are required to clarify the relationships between 
cyclin-dependent kinase pathways, including 
CCND1 and EGFR pathways, and how these 
pathways contribute to tumorigenesis in OSCC.
 In conclusion, copy number changes in CCND1 
or EGFR are frequent events in the carcinogenesis 
of OSCC, and the aberration patterns vary 
between these two genes.  We clearly demon-
strated by dual-color FISH that CCND1 GA is a 
prognostic marker of DFS in OSCC and that 
EGFR BT is a marker of OS.  Simultaneous 
assessment of CCND1 and EGFR statuses by 
means of dual-color FISH is a simple and sensitive 
method of predicting the prognosis of OSCC 
patients.  However, the question of whether the 
genetic proﬁles of these two genes are correlated 
with response to therapy with EGFR inhibitors 
in OSCC was not the focus of this study.  To 
address this issue, further investigations are 
required to determine which kinds of factors, 
including CCND1 and EGFR FISH statuses, can 
be used to identify those patients most likely to 
beneﬁt from EGFR inhibitor therapy.
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